Dermata Therapeutics, Inc. (NASDAQ:DRMAW – Get Free Report) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 480 shares, a decline of 88.6% from the July 15th total of 4,197 shares. Based on an average daily volume of 7,524 shares, the days-to-cover ratio is presently 0.1 days.
Dermata Therapeutics Stock Down 12.5%
Dermata Therapeutics stock traded down $0.00 during midday trading on Wednesday, reaching $0.00. The stock had a trading volume of 47,057 shares, compared to its average volume of 10,802. The firm’s fifty day simple moving average is $0.01 and its 200-day simple moving average is $0.01. Dermata Therapeutics has a 1-year low of $0.00 and a 1-year high of $0.03.
About Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.
The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.
Read More
- Five stocks we like better than Dermata Therapeutics
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
- Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
- Visa’s AI Opportunity Is Hiding in Every Transaction
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
